In the nonobese diabetic (NOD) mouse model of type 1 diabetes (T1D), an insulin peptide (B:9-23) is a major target for pathogenic CD4 + T cells. However, there is no consensus on the relative importance of the various positions or "registers" this peptide can take when bound in the groove of the NOD MHCII molecule, IA g7 . This has hindered structural studies and the tracking of the relevant T cells in vivo with fluorescent peptide-MHCII tetramers. Using mutated B:9-23 peptides and methods for trapping the peptide in particular registers, we show that most, if not all, NOD CD4 + T cells react to B:9-23 bound in low-affinity register 3. However, these T cells can be divided into two types depending on whether their response is improved or inhibited by substituting a glycine for the B:21 glutamic acid at the p8 position of the peptide. On the basis of these findings, we constructed a set of fluorescent insulin-IA g7 tetramers that bind to most insulin-specific Tcell clones tested. A mixture of these tetramers detected a high frequency of B:9-23-reactive CD4 + T cells in the pancreases of prediabetic NOD mice. Our data are consistent with the idea that, within the pancreas, unique processing of insulin generates truncated peptides that lack or contain the B:21 glutamic acid. In the thymus, the absence of this type of processing combined with the low affinity of B:9-23 binding to IA g7 in register 3 may explain the escape of insulin-specific CD4 + T cells from the mechanisms that usually eliminate self-reactive T cells.antigen processing | autoimmunity | T cell receptor | self tolerance I n human type 1 diabetes (T1D) and in the nonobese diabetic (NOD) mouse model of the disease, insulin is a major autoantigen for both B cells and T cells (reviewed in refs. 1, 2). A peptide from the insulin beta chain (B:9-23) has been known for many years to be the major target of insulin-reactive CD4 + T cells in NOD T1D . However, the data suggest that this peptide can bind to the NOD class II major histocompatibility (MHCII), IA g7 , in multiple positions or "registers" within the peptide binding groove (3-7). These registers are defined by the peptide amino acids occupying positions p1-p9 in the groove, which include the "anchor" amino acids at p1, p4, p6, and p9, whose side chains interact with compatible pockets in the MHC groove (8, 9). For an individual peptide, each shift in register puts a new set of peptide amino acids into these anchor positions and brings a different set of peptide amino acid side chains to the surface for potential T-cell recognition, generating a unique ligand. Defining which of the possible B:9-23 binding register(s) in the IA g7 groove create the ligand(s) for diabetogenic insulin-reactive T cells has been difficult, leading to uncertainty in exactly how this peptide is processed and presented to T cells in the pancreas and the inability to construct the relevant fluorescent insulin-IA g7 multimers for in vivo tracking the autoimmune B:9-23-specific T cells.Recently, using techniques to trap versio...